<DOC>
	<DOC>NCT01630252</DOC>
	<brief_summary>This is a prospective, three-part (Part A1, Part A2 and Part B),Phase II study investigating the efficacy, safety, pharmacokinetics and pharmacodynamics of the JNK inhibitor PGL5001 orally administered for up to 5 months with concomitant DMPA administration for the treatment of laparoscopically diagnosed inflammatory endometriosis. The part A1 is open-label, the parts A2 and B are double-blind. The target population will be women of reproductive age and suffering from newly diagnosed peritoneal and/or ovarian endometriosis.</brief_summary>
	<brief_title>PGL5001 Proof of Concept Study in Inflammatory Endometriosis</brief_title>
	<detailed_description />
	<mesh_term>Endometriosis</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<criteria>The Subject must provide written informed consent prior to initiation of any study related procedures. The Subject must be an adult woman of reproductive age, aged from 18 and above. The Subject must be a newly diagnosed patient suffering from peritoneal and/or ovarian endometriosis with at least 15% of the endometriotic lesions observed at the study diagnostic laparoscopy being red inflammatory lesions and with a proven histological diagnosis. The Subject must consent to the scheduling of a second laparoscopy for surgical treatment at the study end. The Subject must have a history of pelvic pain for at least 3 months prior to the screening visit. The Subject is over 40 years old and has a FSH serum level during Day 24 of her cycle â‰¥ 21.5 mIU/ml. The Subject has a positive pregnancy test at baseline or is breastfeeding or planning a pregnancy during the course of the study. The Subject is known for having a cause of chronic abdominal/pelvic pain other than endometriosis (e.g. inflammatory bowel disease, fibromyalgia, interstitial cystitis). The Subject has a history of surgical treatment for endometriosis prior to the study diagnostic laparoscopy. The Subject is requiring urgent surgical excision of endometriotic lesions at the time of first diagnostic laparoscopy. The Subject has a history (in the past 12 months) of or a current medical treatment for endometriosis other than NSAID (e.g. GnRH agonist or antagonist, danazol, continuous oral combined oestroprogestogens).</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>